Precision BioSciences to present late-breaking AASLD 2026 data on PBGENE-HBV study
DTIL•Precision BioSciences secured a late-breaking oral presentation slot for its PBGENE-HBV clinical program at AASLD’s Liver Meeting 2026. The abstract reports durable loss of a key viral RNA signal in HBeAg-positive and HBeAg-negative patients; the data are scheduled for Nov. 8 in Denver.
1. Presentation scheduled
Precision BioSciences is scheduled to present PBGENE-HBV data on Nov. 8, 2026, at AASLD’s Liver Meeting in Denver. The abstract reports durable loss of a key viral RNA signal in both HBeAg-positive and HBeAg-negative patients; results have not yet been presented.
